Valuation: Lord Global Corporation

Market Cap 5.28M 4.62M 4.26M 3.92M 7.42M 508M 7.55M 50.86M 19.95M 248M 19.83M 19.4M 856M P/E 2018 *
-
P/E 2019 -0.6x
Enterprise Value 5.89M 5.15M 4.75M 4.37M 8.27M 567M 8.41M 56.71M 22.25M 277M 22.12M 21.63M 955M EV / Sales 2018
1,290x
EV / Sales 2019 1,135x
Free-Float
25.63%
Yield 2018 *
-
Yield 2019 -
1 week 0
Extreme 0.0002
0
1 month 0
Extreme 0.0002
0
Current year 0
Extreme 0.0002
0
1 year 0
Extreme 0.0002
0
3 years 0
Extreme 0.0001
0
5 years 0
Extreme 0.0001
1
10 years 0
Extreme 0
200,000
Manager TitleAgeSince
Chief Executive Officer 36 2020-01-23
Director TitleAgeSince
Chairman 36 2020-01-23
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%+100.00% 372
+1.43%-5.13%-28.63%-42.04% 10.21B
+1.51%-0.88%+90.98%+102.31% 9.25B
+1.56%+0.07%-17.67%+21.90% 7.01B
+7.65%+5.27%-36.00%+46.63% 4.99B
+0.46%+3.52%+3.76%-3.61% 4.29B
+3.57%+2.65%-30.19%-56.57% 4.03B
+5.04%+2.80%+108.98%+83.94% 3.86B
+4.22%-12.56%+11.11%-16.56% 3.33B
+2.55%+1.97%-5.24%+3.13% 1.95B
Average +2.79%-2.07%+9.71%+23.91% 4.89B
Weighted average by Cap. +2.69%-2.69%+12.03%+19.12%

Financials

2018 2019
Net sales 2.83K 2.47K 2.28K 2.1K 3.97K 272K 4.04K 27.22K 10.68K 133K 10.62K 10.38K 458K 888 776.38 716.2 658.36 1.25K 85.44K 1.27K 8.55K 3.35K 41.76K 3.33K 3.26K 144K
Net income -6.43M -5.62M -5.19M -4.77M -9.04M -619M -9.19M -61.94M -24.3M -303M -24.16M -23.63M -1.04B -491K -429K -396K -364K -689K -47.22M -701K -4.72M -1.85M -23.08M -1.84M -1.8M -79.55M
Net Debt 651K 569K 525K 482K 914K 62.59M 929K 6.26M 2.46M 30.59M 2.44M 2.39M 105M 608K 531K 490K 451K 854K 58.47M 868K 5.85M 2.3M 28.58M 2.28M 2.23M 98.51M
Logo Lord Global Corporation
27 Health Holdings Corp., formerly Lord Global Corporation, is focused on the business development of its 27Health Inc. subsidiary. 27Health Inc. is focused on financing and marketing, healthcare-related products. The Company distributes the Virolens product in Asia, Australia, New Zealand and other Oceania countries. The Virolens system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera attached to a microscope to analyze saliva samples, with the data run through a computer that is trained to identify the virus from other cells, delivering a result in just 20 seconds. The Virolens system was trained to recognize the COVID-19 virus particles in saliva using a range of samples of COVID-19 virus provided by virologists working on the virus at the University of Bristol.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. LRDG Stock